Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fludarabine Phosphate

FDA-approved product (injectable, injection), marketed as Fludara, Fludarabine Phosphate, Oforta.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Fludarabine Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Purine analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli44.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fludarabine Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fludarabine Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)

    NCT06752876 · start 2027-12

    Registered record
    Registry ID
    NCT06752876
    Conditions
    Systemic Lupus Erythematosus; Lupus; Lupus Erythematosus; Lupus Nephritis
    Interventions
    CB-010
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2027-12
    Completion
    2029-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Lupus Erythematosus; Lupus; Lupus Erythematosus; Lupus Nephritis
    InterventionCB-010
    PhasePhase 1
    Registry statusWithdrawn

  • A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

    NCT06984341 · start 2026-06-30

    Registered record
    Registry ID
    NCT06984341
    Conditions
    Systemic Lupus Erythematosus
    Interventions
    P-CD19CD20-ALLO1 Cells; Cyclophosphamide; Fludarabine; Rimiducid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2026-06-30
    Completion
    2033-11-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Lupus Erythematosus
    InterventionP-CD19CD20-ALLO1 Cells; Cyclophosphamide; Fludarabine; Rimiducid
    PhasePhase 1
    Registry statusWithdrawn

  • Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

    NCT07252050 · start 2026-06-08

    Registered record
    Registry ID
    NCT07252050
    Conditions
    Sickle Cell Disease; Hematopoetic Stem Cell Transplant; Haploidentical Hematopoietic Stem Cell Transplant; Haploidentical Stem Cell Transplantation; Graft Failure
    Interventions
    Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-06-08
    Completion
    2029-11-19
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSickle Cell Disease; Hematopoetic Stem Cell Transplant; Haploidentical Hematopoietic Stem Cell Transplant; Haploidentical Stem Cell Transplantation +1 more
    InterventionRuxolitinib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML

    NCT07572695 · start 2026-04-30

    Registered record
    Registry ID
    NCT07572695
    Conditions
    Acute Myeloid Leukemia; Relapsed/Refractory Acute Myeloid Leukemia; AML, Relapsed/Refractory
    Interventions
    Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT); Post-transplant Maintenance Therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-04-30
    Completion
    2028-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Relapsed/Refractory Acute Myeloid Leukemia; AML, Relapsed/Refractory
    InterventionHaploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT); Post-transplant Maintenance Therapy
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

    NCT07502287 · start 2026-03-02

    Registered record
    Registry ID
    NCT07502287
    Conditions
    Relapsed Neuroblastoma; Refractory Neuroblastoma; High-Risk Neuroblastoma; Ganglioneuroblastoma
    Interventions
    EB-DTNB-NK; Fludarabine; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-03-02
    Completion
    2028-06-17
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Neuroblastoma; Refractory Neuroblastoma; High-Risk Neuroblastoma; Ganglioneuroblastoma
    InterventionEB-DTNB-NK; Fludarabine; Cyclophosphamide
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases

    NCT07283315 · start 2025-12-03

    Registered record
    Registry ID
    NCT07283315
    Conditions
    Paediatric B Cell-related Autoimmune Diseases; Autoimmune Diseases; CAR
    Interventions
    anti-CD19/BCMA CAR NK cells (KN5601-K)
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2025-12-03
    Completion
    2029-12-30
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPaediatric B Cell-related Autoimmune Diseases; Autoimmune Diseases; CAR
    Interventionanti-CD19/BCMA CAR NK cells (KN5601-K)
    PhaseEarly phase 1
    Registry statusRecruiting

  • A Study to Determine the Safety and Effectiveness of the Investigational Cellular Therapy GCAR1 in a Patient With Alveolar Soft Part Sarcoma

    NCT07104682 · start 2025-08-21

    Registered record
    Registry ID
    NCT07104682
    Conditions
    Alveolar Soft Part Sarcoma (ASPS); Sarcoma
    Interventions
    GCAR1
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Active not recruiting
    Start
    2025-08-21
    Completion
    2027-01-19
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlveolar Soft Part Sarcoma (ASPS); Sarcoma
    InterventionGCAR1
    PhaseEarly phase 1
    Registry statusActive not recruiting

  • A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases

    NCT07275736 · start 2025-03-01

    Registered record
    Registry ID
    NCT07275736
    Conditions
    Neurological Autoimmune Diseases
    Interventions
    CNCT19 cell injection
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2025-03-01
    Completion
    2029-06-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurological Autoimmune Diseases
    InterventionCNCT19 cell injection
    PhaseEarly phase 1
    Registry statusRecruiting

  • SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    NCT06743126 · start 2025-01-14

    Registered record
    Registry ID
    NCT06743126
    Conditions
    Melanoma, Cutaneous Malignant
    Interventions
    IMA203; nivolumab plus relatlimab; lifileucel; nivolumab; pembrolizumab; ipilimumab; Dacarbazine; temozolomide; paclitaxel; paclitaxel plus carboplatin; Albumin-Bound Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-01-14
    Completion
    2031-10
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma, Cutaneous Malignant
    InterventionIMA203; nivolumab plus relatlimab; lifileucel; nivolumab +7 more
    PhasePhase 3
    Registry statusRecruiting

  • Phase 2 Study of Rapcabtagene Autoleucel in Myositis

    NCT06665256 · start 2024-12-17

    Registered record
    Registry ID
    NCT06665256
    Conditions
    Idiopathic Inflammatory Myopathies
    Interventions
    Rapcabtagene autoleucel; Active Comparator Option
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-12-17
    Completion
    2032-11-29
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Inflammatory Myopathies
    InterventionRapcabtagene autoleucel; Active Comparator Option
    PhasePhase 2
    Registry statusActive not recruiting

  • A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

    NCT06375993 · start 2024-11-10

    Registered record
    Registry ID
    NCT06375993
    Conditions
    Lupus Nephritis; Autoimmune Diseases; Systemic Sclerosis (SSc); Systemic Lupus Erythematosus (SLE); ANCA-Associated Vasculitis (AAV); Idiopathic Inflammatory Myopathies; Stiff Person Syndrome
    Interventions
    ADI-001; Fludarabine; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Enrolling by invitation
    Start
    2024-11-10
    Completion
    2027-12
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus Nephritis; Autoimmune Diseases; Systemic Sclerosis (SSc); Systemic Lupus Erythematosus (SLE) +3 more
    InterventionADI-001; Fludarabine; Cyclophosphamide
    PhasePhase 1
    Registry statusEnrolling by invitation

  • Twice-per-weekSelinexor, 2 Days Melphalan

    NCT06613035 · start 2024-09-30

    Registered record
    Registry ID
    NCT06613035
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Selinexor; Melphalan; Intravenous Busulfan; Fludarabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2024-09-30
    Completion
    2027-09-30
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionSelinexor; Melphalan; Intravenous Busulfan; Fludarabine
    PhasePhase 3
    Registry statusNot yet recruiting

  • Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

    NCT05110742 · start 2024-04-22

    Registered record
    Registry ID
    NCT05110742
    Conditions
    Hematological Malignancy
    Interventions
    Fludarabine Phosphate; Cyclophosphamide; CAR.5/IL15-transduced CB-NK cells
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-04-22
    Completion
    2030-12-31
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematological Malignancy
    InterventionFludarabine Phosphate; Cyclophosphamide; CAR.5/IL15-transduced CB-NK cells
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL

    NCT06064903 · start 2024-04-21

    Registered record
    Registry ID
    NCT06064903
    Conditions
    T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
    Interventions
    CD7-CART01
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-04-21
    Completion
    2040-09-30
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionT-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
    InterventionCD7-CART01
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases

    NCT06243159 · start 2024-02-08

    Registered record
    Registry ID
    NCT06243159
    Conditions
    Autoimmune Diseases
    Interventions
    JY231
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2024-02-08
    Completion
    2026-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutoimmune Diseases
    InterventionJY231
    PhaseEarly phase 1
    Registry statusNot yet recruiting